Gå til indhold
One mature man at home witting worried at the table with stress and depression Concept of life problems and worried people. Adult man looking for solutions at home. Sadness and loneliness condition

Blood management in psychiatry

Blodmonitorering til compliant clozapinbehandling –
uanset hvor og hvornår

Clozapin anses for at være guldstandarden til behandling af TRS (treatment-resistant schizophrenia) med overlegne effekter såsom bedre behandlingsadhærens, lavere samlet dødelighed og færre selvmord samt mindre misbrug af stoffer og alkohol.1

Behandling med clozapin kræver obligatorisk blodmonitorering af leukocyttal og absolut neutrofiltal.2

HemoCue® WBC DIFF System giver en unik mulighed for at teste og få pålidelige resultater direkte ved point of care, hvilket øger sandsynligheden for vellykket monitorering og samtidig skaber et trygt miljø for patienten.

Vil du vide mere om, hvordan point-of-care-testning kan styrke dine behandlingsplaner for patienter med TRS?

Udfyld formularen for at blive kontaktet

Hvad er TRS (treatment-resistant schizophrenia)?

Midsection of unrecognizable White woman struggling with anxiety and cracking her knuckles while contemplating problems.

 

 

Omkring 1/3 af alle patienter med skizofreni er behandlingsresistente, defineret som utilstrækkelig respons på to forskellige antipsykotika.3

Patienter med TRS har dårligere behandlingsresultater med færre funktionelle milepæle i hverdagen, herunder lavere ægteskabsrater, højere forekomst af stof- eller alkoholmisbrug og større sandsynlighed for ophold på institutioner.1

Anvendelsen af clozapin blandt patienter med skizofreni varierer betydeligt mellem lande – men er markant underanvendt i de fleste regioner.3

Udfordringer ved behandling af
patienter med TRS

En væsentlig ulempe ved clozapin er den øgede risiko for at udvikle granulocytopeni eller endda agranulocytose (hos 0,4 % af patienterne).3

Dette medfører en øget risiko for infektioner, som – hvis de ikke diagnosticeres og behandles – kan være livstruende. Derfor kræver disse patienter omfattende monitorering af leukocyttal.4

Blodmonitorering anses for at være en væsentlig faktor i den manglende anvendelse af clozapinordinationer.5

Testning under clozapinbehandling
ved point of care

Konklusive resultater, der kan understøtte behandlingsbeslutninger – og spare tid for både dig og dine patienter

HemoCue® WBC DIFF System giver en unik mulighed for at teste og få pålidelige resultater for WBC + ANC (absolut neutrofiltal) direkte ved point of care.

Vælg mellem venøse eller kapillære blodprøver, og undgå ubehag forbundet med testning eller forsendelse af prøver til laboratoriet.

På blot 5 minutter leverer HemoCue® WBC DIFF System konklusive resultater, der kan understøtte behandlingsbeslutninger – og spare tid for både dig og dine patienter.

01

Forenklet blodmonitorering – uanset hvor og hvornår

HemoCue® WBC DIFF System offers the unique possibility of testing and receiving reliable results for WBC + ANC right at the point of care. In just five minutes, you can access results that can guide treatment decisions, saving time for both you and your patients.

 

  • The only “true” POC system for WBC + ANC
    HemoCue® WBC DIFF System gives a lab accurate total white blood cell count as well as a 5-part differential – right where and when needed
  • Lightweight and with a small footprint
    Using a portable device means that it’s easy to bring to the where the patients are
  • Battery operated system
    Don’t worry about finding a power socket, benefit from using HemoCue® WBC DIFF System with 6 type C alkaline batteries
  • Immediate access 24/7
    Easy to use by HCP after a brief training

02

Patientvenlig blodmonitorering til compliant clozapinbehandling

Choose between venous or capillary blood samples and prevent any discomfort caused by testing at or sending samples to the lab.

 

  • Capillary sampling as an attractive solution for needle-adverse patients – choose between venous or capillary blood samples, and prevent any discomfort caused by testing at or sending samples to the lab
  • Minimal blood volume required – one single drop of blood is enough for measuring with HemoCue® WBC DIFF System
  • Routines that provide comfort for the patient – Create a safe space and increase the likelihood of successful monitoring by having a well-known HCP perform the test. Minimize the worry and stress of catching appointments at the lab
  • Improved adherence to treatment regimes
    A patient-friendly experience increases chances of following treatment plans

 

03

Hurtigere behandlingsbeslutninger og strømlinet arbejdsgang i tre enkle trin

In just 5 minutes, HemoCue® WBC DIFF System provides conclusive results that can guide treatment decisions – saving time for both you and your patients.

 

  • Flexible testing for improved workflow
    A flexible testing procedure enables you to keep an efficient workflow even when testing has not been done beforehand
  • 3 simple steps
    HemoCue® WBC DIFF System offers a simple test procedure, that can be handled by HCP after a brief training
  • Quick TAT
    HemoCue® WBC DIFF System provides results for WBC + ANC in just 5 minutes
  • Hassle-free data transfer
    With the built-in data management features, data can be easily and securely transferred from analyzer to HIS/LIS
Step 1 - How to use the HemoCue® WBC DIFF System
01

Fyld mikroküvetten

Step 2 - How to use the HemoCue® WBC DIFF System
02

Placer mikroküvetten i analysatoren

Step 3 - How to use the HemoCue® WBC DIFF System
03

Se resultater inden for 5 minutter

HemoCue® WBC DIFF System

Doctor and patient in health care environment with WBC DIFF- white blood monitor system.

 

The HemoCue® WBC DIFF System brings the unique benefit of total white blood cell (WBC) count with a 5-part differential within minutes, enabling faster care while saving valuable time and money with a more streamlined workflow.

Go to the product page to learn more

Kundehistorie

WeMind er en svensk udbyder af psykiatrisk sundhedspleje, grundlagt i 2006. I løbet af de seneste år er WeMind vokset til at blive den største private udbyder inden for psykiatri med klinikker i Stockholm, Göteborg og Skåne-regionen. I Nacka findes der en specialiseret klinik for voksne patienter med behov for psykiatrisk vurdering, udredning og behandling.

Valeria Grevsten, overlæge i teamet for psykotiske lidelser hos WeMind i Nacka, har det overordnede ansvar for tilrettelæggelsen af behandlingen af psykotiske lidelser i den sydøstlige del af Stockholm (herunder klinikker i Nacka, Värmdö, Tyresö, Haninge og Nynäshamn).

Læs hendes historie og få indsigt i, hvordan implementeringen af systemet har gavnet deres praksis.

Read the story

Ofte stillede spørgsmål

Som angivet i IFU (brugsanvisningen) anbefales det at verificere uventede resultater ved hjælp af venøst blod eller at bekræfte resultaterne med en alternativ metode.

Du kan finde instruktionsvideoer til alle systemer i vores Knowledge Center.

Et resultat for leukocyttal skal altid fortolkes i sammenhæng med patientens sygehistorie og andre kliniske tegn. HemoCue® WBC DIFF System viser en markering eller en fejlkode, hvis der registreres et problem i systemet eller med prøverne. Forklaringer og anbefalede handlinger for hver markering eller fejlkode er beskrevet i manualen.

Kontakt os for mere information

References

1 Nucifora et al. Treatment Resistant Schizophrenia: Clinical, Biological, and Therapeutic Perspectives. Neurobiology of Disease 2019: 131. DOI: 10.1016/j.nbd.2018.08.016.

2 European Medicines Agency (EMA), 2002. Committee for proprietary medicinal products (CPMP): summary information on referral opinion following arbitration pursuant to article 30 of council directive 2001/83/EC for Leponex and associated names. https://www.ema.europa.eu/en/documents/referral/summary-information-referral-opinion-following-arbitration-pursuant-article-30-council-directive-200183ec-leponex-and-associated-names-international-non-proprietary-name-inn-clozapine-background_en.pdf Accessed October 28, 2024.

3 Jakobsen et al. Antipsychotic prescribing practices for outpatients with schizophrenia and reasons for non-clozapine treatment – Data from a Danish quality assessment audit. Nordic Journal of Psychiatry 2023, Vol 77(5):481-490.

4 Li et al. The prevalence of agranulocytosis and related death in clozapine-treated patients: a comprehensive meta-analysis of observational studies. Psychological Medicine 2020, Vol 50;583–594.

5 Nielsen et al. Psychiatrists’ attitude towards and knowledge of clozapine treatment. Journal of Psychopharmacology 2010, 24(7): 965–971.